Results 101 to 110 of about 27,657 (222)
Benign by design: A paradigm shift in cosmetic ingredient development
International Journal of Cosmetic Science, EarlyView.Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota +3 more
wiley +1 more source
Safety and efficacy of rosiglitazone in the elderly diabetic patient
, 2009 Adie Viljoen1, Alan Sinclair21Department of Chemical Pathology, Lister Hospital, Stevenage, Hertfordshire, UK; 2Bedfordshire and Hertfordshire Postgraduate Medical School, Putteridge Bury ampus, Luton, Bedfordshire, UKAbstract: Diabetes is an important ...
Alan Sinclair, Adie Viljoen
core
Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes
, 2010 Interleukin (IL)-6, a proinflammatory cytokine, stimulates adipocyte lipolysis and induces insulin resistance in obese and diabetic subjects. However, the effects of the anti-diabetic drug rosiglitazone on IL-6-stimulated lipolysis and the underlying ...
Yongqing Yang, Gongshe Yang
core +1 more source
Journal of Diabetes Investigation, EarlyView.Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi +4 more
wiley +1 more source
The Effect of PPAR Agonists on the Migration of Mature and Immature Eosinophils
PPAR Research, 2012 PPARγ agonists can either enhance or inhibit eosinophil migration, which is a sum of directional migration (chemotaxis) and random cell movement (chemokinesis). To date, the effects of PPAR agonists on chemokinesis have not been examined.
Steven G. Smith +6 more
doaj +1 more source
The anti-atherogenic effects of thiazolidinediones
, 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced
Stojanovska, Lily +3 more
core
ChemistryOpen, Volume 15, Issue 7, July 2026.Epoxy Clerodane Diterpene (ECD) significantly reduces adipocyte hypertrophy and lipid accumulation in human mesenchymal stem cell (hMSC)‐derived adipocytes. ECD improves mitochondrial membrane potential (ΔΨm), increases thermogenic regulators (UCP‐1, PPARγC1α), decreases adipogenic markers (C/EBPα, PPARγ), and reduces inflammatory mediators (TNF‐α, NF ...
Sahar Abdulaziz AlSedairy +4 more
wiley +1 more source
Normal homeostatic hematopoiesis in rosiglitazone-treated mice.
, 2016 (A) Adipocytes in tibia BM sections from rosiglitazone-treated and control mice (HE staining, scale bar 200 μm).(B) Adipocyte counts per mm2 in tibia BM sections from both groups of mice.
Wenyi Lu (701872) +4 more
core +1 more source
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal [PDF]
, 2011 OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
null null
core +1 more source
Neurobiology of Disease, 2010 Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, which is an anti-diabetic agent against type 2 diabetes, is currently in Phase III ...
Seung-Yong Yoon +6 more
doaj +1 more source